TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SynAct Pharma AB ( (SE:SYNACT) ) has provided an announcement.
SynAct Pharma AB has announced an increase in its number of shares and votes by 1,004,100 due to the conversion of warrants in August 2025. This conversion has generated SEK 17.7 million for the company, potentially strengthening its financial position and supporting its ongoing efforts in the biotechnology sector.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical stage biotechnology company specializing in resolving inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory effects in autoimmune and inflammatory diseases, aiming to help patients achieve immune balance.
Average Trading Volume: 172,427
Technical Sentiment Signal: Sell
Current Market Cap: SEK946.1M
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.